Real-World Studies
Prospective Bladder Cancer Infrastructure (ProBCI)
Uunk et alESMO Real-World Data and Digital Oncology
The Dutch Prospective Bladder Cancer Infrastructure (ProBCI) has marked five years of operations as a nationwide real-world data and biospecimen platform for bladder cancer research. Established in 2020, ProBCI captures patients diagnosed with high-risk non-muscle-invasive bladder cancer (HR-NMIBC), muscle-invasive bladder cancer (MIBC), and metastatic bladder cancer (mBC) throughout the Netherlands.
The infrastructure operates via a two-tier framework embedded within the Netherlands Cancer Registry (NCR): • Full Cohort: A population-based registry encompassing all eligible patients, capturing standard core clinical parameters for HR-NMIBC and MIBC, and extended clinical datasets for mBC. As of January 1, 2026, this cohort comprises 20,737 patients. • Active Cohort: A prospective subcohort of patients recruited across 24 participating hospitals who provide informed consent for longitudinal follow-up until death, longitudinal patient-reported outcomes (PROs), and biospecimen collection. To date, 1,519 patients have been enrolled, demonstrating high engagement with 91% providing blood samples and 73% completing baseline quality-of-life questionnaires.
Data and biospecimens derived from ProBCI are actively utilized to power real-world studies, including nationwide epidemiological characterizations, translational biomarker validation, and the establishment of concurrent external control cohorts for single-arm clinical trials.
Key Takeaways
- The nationwide ProBCI registry has accrued 20,737 bladder cancer patients in its population-based full cohort and 1,519 prospectively enrolled patients across 24 participating centers in its active cohort.
- Among prospectively enrolled active cohort participants, 91% provided blood specimens for biobanking and 73% completed baseline patient-reported outcome questionnaires.
Read the original sourceESMO Real-World Data and Digital Oncology
